Autolus Therapeutics plc Increase (Decrease) in Deferred Income Taxes
Autolus Therapeutics plc (AUTL) reported Increase (Decrease) in Deferred Income Taxes of -$772.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredIncomeTaxes · last filed 2026-08-11
- Autolus Therapeutics plc increase (decrease) in deferred income taxes for the quarter ending 2026-06-30 was -$788.00K.
- Autolus Therapeutics plc increase (decrease) in deferred income taxes for the quarter ending 2026-03-31 was $16.00K.
- Autolus Therapeutics plc increase (decrease) in deferred income taxes for the quarter ending 2025-12-31 was $1.17M.
- Autolus Therapeutics plc increase (decrease) in deferred income taxes for the quarter ending 2025-09-30 was -$13.00K, a 107.74% decline year-over-year.
- Autolus Therapeutics plc increase (decrease) in deferred income taxes for fiscal 2025 was $286.00K, a 54.59% increase from fiscal 2024.
- Autolus Therapeutics plc increase (decrease) in deferred income taxes for fiscal 2024 was $185.00K, a 81.24% decline from fiscal 2023.
- Autolus Therapeutics plc increase (decrease) in deferred income taxes for fiscal 2023 was $986.00K, a 267.91% increase from fiscal 2022.
- Autolus Therapeutics plc increase (decrease) in deferred income taxes for fiscal 2022 was $268.00K, a 272.22% increase from fiscal 2021.
| Period end | Increase (Decrease) in Deferred Income Taxes 3 month | Increase (Decrease) in Deferred Income Taxes 3 month as first filed | Increase (Decrease) in Deferred Income Taxes 6 month | Increase (Decrease) in Deferred Income Taxes 9 month | Increase (Decrease) in Deferred Income Taxes 12 month | Increase (Decrease) in Deferred Income Taxes 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | -$788.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$772.00K 10-Q · filed 2026-08-11 | $398.00K derived: sum of 3 quarters · filed 2026-08-11 | $385.00K derived: sum of 4 quarters · filed 2026-08-11 | ||
| 2026-03-31 | $16.00K 10-Q · filed 2026-05-14 | $1.19M derived: sum of 2 quarters · filed 2026-05-14 | $1.17M derived: sum of 3 quarters · filed 2026-05-14 | $789.00K derived: sum of 4 quarters · filed 2026-08-11 | ||
| 2025-12-31 | $1.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $1.16M derived: sum of 2 quarters · filed 2026-03-27 | $773.00K derived: sum of 3 quarters · filed 2026-08-11 | $286.00K 10-K · filed 2026-03-27 | ||
| 2025-09-30 | -$13.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$397.00K derived: sum of 2 quarters · filed 2026-08-11 | -$884.00K 10-Q · filed 2025-11-12 | -$1.02M derived: sum of 4 quarters · filed 2026-08-11 | ||
| 2025-06-30 | -$384.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$871.00K 10-Q · filed 2026-08-11 | -$1.01M derived: sum of 3 quarters · filed 2026-08-11 | -$844.00K derived: sum of 4 quarters · filed 2026-08-11 | ||
| 2025-03-31 | -$487.00K 10-Q · filed 2026-05-14 | -$628.00K derived: sum of 2 quarters · filed 2026-05-14 | -$460.00K derived: sum of 3 quarters · filed 2026-05-14 | -$534.00K derived: sum of 4 quarters · filed 2026-05-14 | ||
| 2024-12-31 | -$141.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $27.00K derived: sum of 2 quarters · filed 2026-03-27 | -$47.00K derived: sum of 3 quarters · filed 2026-03-27 | $185.00K 10-K · filed 2026-03-27 | ||
| 2024-09-30 | $168.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $94.00K derived: sum of 2 quarters · filed 2025-11-12 | $326.00K 10-Q · filed 2025-11-12 | $792.00K derived: sum of 4 quarters · filed 2025-11-12 | ||
| 2024-06-30 | -$74.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $158.00K 10-Q · filed 2025-08-12 | $624.00K derived: sum of 3 quarters · filed 2025-08-12 | $862.00K derived: sum of 4 quarters · filed 2025-08-12 | ||
| 2024-03-31 | $232.00K 10-Q · filed 2025-05-08 | $698.00K derived: sum of 2 quarters · filed 2025-05-08 | $936.00K derived: sum of 3 quarters · filed 2025-05-08 | $1.02M derived: sum of 4 quarters · filed 2025-05-08 | ||
| 2023-12-31 | $466.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $704.00K derived: sum of 2 quarters · filed 2025-03-20 | $791.00K derived: sum of 3 quarters · filed 2025-03-20 | $986.00K 10-K · filed 2025-03-20 | ||
| 2023-09-30 | $238.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $325.00K derived: sum of 2 quarters · filed 2024-11-12 | $520.00K 10-Q · filed 2024-11-12 | $201.00K derived: sum of 4 quarters · filed 2024-11-12 | ||
| 2023-06-30 | $87.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $282.00K 10-Q · filed 2024-08-08 | -$37.00K derived: sum of 3 quarters · filed 2024-08-08 | |||
| 2023-03-31 | $195.00K 10-Q · filed 2024-05-17 | -$124.00K derived: sum of 2 quarters · filed 2024-05-17 | ||||
| 2022-12-31 | -$319.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $268.00K 10-K · filed 2024-03-21 | ||||
| 2022-09-30 | $587.00K 10-Q · filed 2023-11-09 | |||||
| 2021-12-31 | $72.00K 10-K · filed 2024-03-21 | |||||
| 2021-03-31 | $280.00K 6-K · filed 2021-05-06 | |||||
| 2020-12-31 | $1.34M 20-F · filed 2021-03-04 | |||||
| 2020-03-31 | $0.00 6-K · filed 2021-05-06 | |||||
| 2019-12-31 | $399.00K 20-F · filed 2021-03-04 | |||||
| 2018-12-31 | $0.00 20-F · filed 2021-03-04 | $1.30M 20-F · filed 2019-02-25 | ||||
| 2018-09-30 | $0.00 20-F · filed 2021-03-04 | $0.00 20-F · filed 2020-03-03 | ||||
| 2017-09-30 | $0.00 20-F · filed 2020-03-03 | $13.50M 20-F · filed 2018-11-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 |